Vylor Confirms Breakthrough Wheat Technology Will Launch in 2027
Get Alerts CTVA Hot Sheet
Join SI Premium – FREE
Company forecasts
The company anticipates that hybrid wheat will accelerate the growth of its
"Wheat is grown on nearly 550 million acres globally and on more than 60 million acres in
Hybrid seeds are created by crossing two genetically different parents to ultimately produce more resilient, higher yielding plants for farmers. Vylor's hybrid wheat is built on a first-of-its kind system, proprietary and non-GMO; it increases yield potential by 10%1 while using the same amount of land and resources, is more resistant to drought – hybrid wheat created using Xpedite can yield up to 20%2 higher than elite varieties in water-stressed environments – and accelerates the speed to market of new elite germplasm by increasing the scale of parent seed production. As a product of conventional breeding, the hybrid wheat Vylor will launch in
|
1 |
Internal yield testing on launch hybrids: three years (2024, 2025, 2026) of testing with 41 locations in |
|
2 |
Internal yield testing on launch hybrids: three years (2024, 2025, 2026) of testing with 20 locations in |
Unlike other wheat hybridization systems that have been known for decades, Vylor's proprietary technology has been shown in trials to work in 100% of wheat germplasm tested – enabling more rapid genetic gains and delivery of seed at a commercial scale. The company expects its hybrid wheat technology will, when compared to conventional wheat, double the rate of annual genetic gain by 2040.
Vylor's hybrid wheat delivers grain meeting the same quality standards as varietal wheat and requires no special equipment or management, allowing farmers to maintain their current farming practices. The company will launch Hard Red Winter wheat in 2027 in
Click here to watch the Vylor video about the science of hybrid wheat.
Cautionary and Forward-Looking Statements
Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: Corteva and its respective representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in the company's other filings with the Securities and Exchange Commission ("SEC"), and in presentations, reports or letters to its stockholders.
In some cases, the company identified these forward-looking statements by such words or phrases as "plans," "outlook," "will," "is designed to," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends," or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on the company's current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of Corteva's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K, the "Risk Factors" and "Cautionary Statement Concerning Forward-Looking Statements" sections of the preliminary information statement filed as Exhibit 99.1 to Vylor Inc.'s ("Vylor") Registration Statement on Form 10, as amended, and to similar risk factors and cautionary statements in all other reports and forms filed with the SEC.
We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement. We specifically decline to undertake any obligation, and specifically disclaim any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.
Examples of forward-looking statements include, but are not limited to, Corteva's intent to separate and its related expectations for Corteva and Vylor, including the anticipated timing, attributes, performance and financial, competitive and other benefits of these and any other products in Vylor's pipeline. These forward-looking statements reflect management's current expectations and are not guarantees of future performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond Corteva's control.
About Vylor
Vylor is an advanced seed and genetics company that has, for more than a century, been focused on delivering groundbreaking innovation to farmers. Anchored in the agriculture industry's most elite germplasm and transformative biotech, Vylor leverages its scientific expertise to deliver next generation technology to help farmers around the world boost yields. With its expertise in advanced science, leading routes-to-market and an expanding licensing business, Vylor drives value and delivers growth for farmers, customers and shareholders – and in doing so, helps feed, fuel and clothe the world. More information at vylor.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vylor-confirms-breakthrough-wheat-technology-will-launch-in-2027-302878865.html
SOURCE Corteva Agriscience
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Datavault AI launches rights offering of up to $125M
- VEON launches $200 million share buyback program for 3.9% of shares
- ANI Pharmaceuticals gets FDA approval for generic everolimus suspension
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share